Kidney complication trial for sickle cell disease scrapped before start
NCT ID NCT06286046
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study aimed to test the drug mitapivat in people with sickle cell disease who also have kidney damage (nephropathy). The goal was to see if mitapivat could reduce protein in the urine, a sign of kidney stress. The trial was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.